I'm broadly encouraged, although I wanted to hear more about the three GLP-1 agonist assets ... but some face patent expirations in the near-to-medium term, while other, newer products are ...

Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of ... That result sparked a near-5% increase in Roche's share price, and the latest announcement had ...

It was wild and so hard to describe, but think about being near a stream ... healthy for me and my family, and not gain back what I lost.” Personal testimonials about GLP-1 agonists show the ...

ResMed’s valuation now looks slightly stretched, however a supportive near ... me. There is one rather obvious factor that could contribute to a person taking up and continuing to use both GLP-1 ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

I would have told you that I had been fat my whole life. I had complete confidence that this was true ― until the photos ...

Finding stocks with the potential to double in just three years is no easy feat, even in this bull market. Plenty of ...

The 63-year-old CEO of Life Time Fitness says people always want to know his workout and supplement prescription. Here's how ...

Eli Lilly 's blockbuster weight loss drugs, and questions about its valuation. Then, Ricky continues his conversation with ...

I figured that eating more protein would give me more energy and steer the fragile container that is my body in the right ...